Vistin Pharma ASA : Proposal for Extraordinary Dividend
(Thomson Reuters ONE) -
Oslo, Norway, 9 October 2017
Norwegian pharmaceutical company Vistin Pharma ASA ("Vistin Pharma") announced
today that the Board of Vistin Pharma will propose an extraordinary dividend of
NOK 7.00 per share.
On 2 October, the Company announced the successful completion of the sale of its
opioids and tablet manufacturing business to TPI Enterprises Limited, which
resulted in the receipt of a provisional cash consideration of NOK 159.5
million. The sale is expected to have a positive net cash effect of NOK 140 -
150 million, before any transaction costs. As a result of this sale, the Board
will call for an extraordinary general meeting to approve a dividend of NOK
7.00 per share (NOK 119.4 million).
Following the sale, Vistin Pharma is a pure play metformin producer, with a
strong position in the global metformin market. The global market for metformin
is expected to grow by four to five percent per annum, and Vistin Pharma is
attractively positioned to capture part of this growth. The Company's project to
double the production capacity for metformin is progressing according to plan,
and the project will be presented in further details in the third quarter
financial report to be released on 27 October.
For further information, please contact:
Kjell-Erik Nordby
CEO
+47 91 36 42 80
kjell-erik.nordby(at)vistin.com
Gunnar Manum
CFO
+47 95 17 91 90
gunnar.manum(at)vistin.com
This information is subject to the disclosure requirements pursuant to section
5-12 of the Norwegian Securities Trading Act.
This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Vistin Pharma ASA via GlobeNewswire
Datum: 09.10.2017 - 14:33 Uhr
Sprache: Deutsch
News-ID 562896
Anzahl Zeichen: 2182
contact information:
Town:
Oslo
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 185 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Vistin Pharma ASA : Proposal for Extraordinary Dividend"
steht unter der journalistisch-redaktionellen Verantwortung von
Vistin Pharma ASA (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
